Literature DB >> 7884649

Effects of bladder resorption on pharmacokinetic data analysis.

J T Dalton1, M G Weintjes, J L Au.   

Abstract

In modern pharmacokinetic analysis, the urinary bladder is usually viewed as a nonreturning compartment or storage site for renally excreted compounds. Our previous studies have indicated appreciable bladder resorption of drugs. The present study used computer simulations to evaluate the quantitative importance of several potential determinants of bladder resorption, namely the bladder resorption rate constant (ka), interval between bladder voiding (delta tvoid), ratio of renal elimination rate constant to overall elimination rate constant (ex:kel ratio), and kel or t1/2. The data identified ka, delta tvoid, and kex:kel ratio as the three most important determinants of the rate and extent of bladder resorption. We further examined the errors introduced in the derived pharmacokinetic parameters due to omission of bladder resorption. Plasma concentration-time profiles and urinary excretion-time profiles were generated by simulations using different values of ka, delta tvoid, and kex:kel ratio. These profiles were used to derive the pharmacokinetic parameters, including the renal clearance (CLrenal), total body clearance (CLtotal), nonrenal clearance (CLnonrenal), t1/2, mean residence time (MRT), amount and fraction of dose excreted in urine (Aex and fe), and volume of distribution at steady state (Vdss). Data show that resorption of drug from the bladder into the systemic circulation increased the area under the plasma concentration-time profile, MRT and t1/2, but decreased CLrenal, CLtotal, Aex, and Fe. Vdss was relatively unchanged. Overestimation of MRT and t1/2 was dependent on ka, kex:kel ratio, and delta tvoid. Underestimation in CLrenal), Aex, and fe was not dependent on the Kex:kel ratio, but was affected by changes in ka and delta tvoid. CLrenal and fe were the most sensitive pharmacokinetic parameters, with a > or = 50% underestimation at a ka value that we reported previously, for the bladder absorption of antipyrine in rats with intact urothelium. In summary, these data indicate (i) alteration in the plasma concentration-time profiles and urinary excretion-time profiles due to bladder resorption, and (ii) substantial over- or underestimation in the derived pharmacokinetic parameters due to erroneous omission of bladder resorption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884649     DOI: 10.1007/bf02353328

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  23 in total

1.  STUDIES ON THE MECHANISMS OF DRUG MOVEMENT FROM THE ISOLATED URINARY BLADDER.

Authors:  J F BORZELLECA
Journal:  J Pharmacol Exp Ther       Date:  1965-04       Impact factor: 4.030

2.  Evidence of significant absorption of sodium salicylate from urinary bladder of rats.

Authors:  J L Au; J T Dalton; M G Wientjes
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

3.  Effect of distension on blood flow in dog's urinary bladder.

Authors:  A Finkbeiner; J Lapides
Journal:  Invest Urol       Date:  1974-11

Review 4.  Kinetic implications of drug resorption from the bladder.

Authors:  J H Wood; T W Leonard
Journal:  Drug Metab Rev       Date:  1983       Impact factor: 4.518

5.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine.

Authors:  R A Upton; J N Buskin; R L Williams; N H Holford; S Riegelman
Journal:  J Pharm Sci       Date:  1980-11       Impact factor: 3.534

6.  Studies on the movement of nitrofurantoin across the dog urinary bladder.

Authors:  J D Conklin; R D Hollifield
Journal:  Invest Urol       Date:  1967-11

7.  Permeability of the bladder mucosa to thiotepa, adriamycin, and daunomycin in men and rabbits.

Authors:  M Pavone-Macaluso; N Gebbia; F Biondo; S Bertolini; G Caramia; F P Rizzo
Journal:  Urol Res       Date:  1976-04-21

8.  Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl.

Authors:  F F Kadlubar; K L Dooley; C H Teitel; D W Roberts; R W Benson; M A Butler; J R Bailey; J F Young; P W Skipper; S R Tannenbaum
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

9.  Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.

Authors:  J T Dalton; M G Wientjes; R A Badalament; J R Drago; J L Au
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

10.  Bladder wall penetration of intravesical mitomycin C in dogs.

Authors:  M G Wientjes; J T Dalton; R A Badalament; J R Drago; J L Au
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

View more
  3 in total

Review 1.  Intravesical drug delivery. Pharmacokinetic and clinical considerations.

Authors:  M S Highley; A T van Oosterom; R A Maes; E A De Bruijn
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

Review 2.  Intraperitoneal therapy for peritoneal cancer.

Authors:  Ze Lu; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

3.  Pearls and Pitfalls in Pediatric Kidney Transplantation After 5 Decades.

Authors:  Loes Oomen; Charlotte Bootsma-Robroeks; Elisabeth Cornelissen; Liesbeth de Wall; Wout Feitz
Journal:  Front Pediatr       Date:  2022-04-08       Impact factor: 3.569

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.